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Summary:  In addition to the CD4 threshold of <100 cells/mcL, reflexive CrAg screening 
should be considered in persons failing ART with viral loads ≥5000 copies/mL. 
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Abstract: 
Background: Detectable serum or plasma cryptococcal antigen (CrAg) precedes symptomatic 
cryptococcal meningitis. The World Health Organization (WHO) recommends CrAg screening 
for HIV infected people with CD4<100 cells/mcL initiating antiretroviral therapy (ART). 
However, an increasing proportion of cryptococcosis patients are now ART-experienced. 
Whether CrAg screening is cost-effective in those with virologic failure is unknown.   
Methods:  We retrospectively performed nationwide plasma CrAg testing among ART 
experienced Ugandan adults with virologic failure (≥1,000 copies/mL) using leftover plasma 
after viral load testing during September 2017–January 2018. For those CrAg-positive, we 
obtained ART history, meningitis occurrence, and 6-month survival via medical record review.  
Results: Among 1,186 subjects with virologic failure, 35 (3.0%) were CrAg-positive with 
median ART duration of 41 months (IQR, 10–84 months). Among 25 subjects with 6-month 
outcomes, 16 (64%) survived, 7 (28%) died, and 2 (8%) were lost. One survivor had suffered 
cryptococcal meningitis two years prior. Two others developed cryptococcal meningitis and 
survived. Five survivors were known to have received fluconazole. Thus, meningitis-free 
survival at 6-months was 61% (14/23). Overall, 91% (32/35) of CrAg-positive persons had viral 
load ≥5000 copies/mL compared with 64% (735/1,151) of CrAg-negative (Odds Ratio = 6.0; 
95% CI: 1.8-19.8, P = 0.001). CrAg prevalence was 4.2% (32/768) among those with viral loads 
≥5000 copies/mL and 0.7% (3/419) among <5000 copies/mL  
Conclusion: In addition to the CD4 threshold of <100 cells/mcL, reflexive CrAg screening 
should be considered in persons failing ART in Uganda with viral loads ≥5000 copies/mL. 
Keywords: Cryptococcal antigenemia, virologic failure, ART experienced, HIV  
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INTRODUCTION  
Cryptococcal meningitis is responsible for 15% of AIDS-related deaths and is the leading 
cause of adult meningitis in Sub-Saharan Africa (1-2). Annual global deaths from cryptococcosis 
are estimated at 181,100, with 75% of these deaths in Sub-Saharan Africa (1). Cryptococcal 
antigen (CrAg) is an independent predictor of mortality and can be detected in blood by latex 
agglutination a median of three weeks before developing initial symptoms of clinical 
cryptococcosis (3-4). CrAg screening is cost effective, has survival benefit, and is recommended 
by the World Health Organization (WHO) in persons with CD4 count <100 cells/mcL, and can 
be considered below 200 cells/µL (5-9). Among ART-naïve outpatient populations in low and 
middle income countries, the CrAg prevalence in 2014 averages 6% with some regional 
variations (1). Among Ugandan ART-naive outpatients in 2004–2006 with CD4 <100 cells/mcL 
the CrAg prevalence is 8.8% (10). 
There is a substantial proportion of ART-experienced patients with virologic failure 
presenting with fulminant cryptococcosis (11).  During 2013–2017 in Uganda, nearly half of the 
patients presenting with cryptococcal meningitis were ART-experienced (11). These ART-
experienced persons with virologic failure are at risk for cryptococcosis, yet they are not 
included within WHO CrAg screening guidelines’ high risk category (5, 12). As monitoring of 
those receiving ART is scaled up from CD4 to virologic monitoring in resource limited settings, 
CD4-based algorithms for CrAg screening may not be readily applicable to ART-experienced 
populations. Baseline CD4 counts may be performed at HIV diagnosis but not routinely while 
monitoring HIV treatment. The Uganda HIV guidelines 2018  recommend CrAg screening in 
ART naïve or treatment failure patients with CD4 cell counts less than 100cells/mcL (13). In the 
absence of CD4 monitoring, it is unknown whether to screen persons with virologic failure. 
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Given the substantial proportion of ART-experienced patients presenting with 
cryptococcosis, new viral load-based CrAg screening strategies may be useful. Uganda has also 
adopted the ‘test and treat’ strategy which will enroll more people on ART irrespective of their 
CD4 counts. In addition we are now encouraging more virologic monitoring compared to CD4 
monitoring. This creates a challenge for CrAg screening which are based on CD4 counts.  We 
conducted this study to determine the CrAg prevalence and clinical outcomes of CrAg-positive 
persons among ART-experienced people with virologic failure. We evaluated the potential 
threshold of virologic failure where CrAg screening should be considered, and cost of CrAg 
screening at this threshold.    
METHODS 
Study Design, Setting and Participants  
This cross-sectional study was conducted at the Uganda National Health Laboratory Services 
(UNHLS), which performs centralized viral load monitoring in Uganda (~95% of all HIV viral 
load testing). The UNHLS processed a total of 843,020 viral load tests for adults in 2017 of 
which 10% (84302/843020)had unsuppressed viremia of  >1,000 copies/mL (14). Dried blood 
spot and plasma samples from health facilities are delivered to the UNHLS via a hub transport 
system for HIV viral load testing (15). We retrospectively evaluated stored plasma samples of 
1,186 ART-experienced HIV-infected adults (≥18 years) with suspected virologic failure with 
HIV viral loads above >1,000 copies/mL. The sample size was estimated using Buderer’s 
formula (using an absolute precision of 0.1, a confidence Interval of 95%, an estimated 
prevalence of 8.9%(from a CrAg study in Nigeria which had largely ART experienced people; 
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(16)) and assumed a sensitivity of 50% giving us 1079 subjects to which we added a 10% margin 
for possible missing samples making a total of 1186 subjects. We tested left over plasma samples 
after viral load testing from specimens collected during September 2017–January 2018. The 
samples from September 2017- January 2018 were the most recent easily accessible and 
retrievable samples. We didn’t have stored samples of plasma for patients who had dried blood 
spots. CrAg LFA testing on dried blood spots has lower sensitivity compared to plasma 
(unpublished data). CrAg testing was performed from March to July 2018 followed by 
retrospective chart review to determine 6-month outcomes for the CrAg-positive patients.  
Study procedures 
Using the UNHLS database, we identified all patients with virologic failure and left over 
plasma samples from the months of September 2017 to January 2018.  From these we selected a 
random sample of 1186 patients with left over samples using an auto generated command in 
Stata 14 (Stata Corp, College Station, TX, USA). The sampling technique used draws observations 
without replacement from a dataset. Quantitative RNA viral loads on plasma had been done by 
UNHLS using the COBAS AmpliPrep/ COBASTaqMan system. For this study, we performed 
CrAg testing on stored plasma samples at UNHLS; CrAg testing was performed using the CrAg 
lateral flow assay (LFA) (IMMY Inc., Norman, Oklahoma, USA).  
Subjects’ demographics and clinical data were obtained from the viral load testing laboratory 
request forms. Outcome data were obtained by chart review and/or contacting health facility 
clinicians. Additionally, clinicians were duly informed of the positive CrAg results. Patients who 
had not had any interaction with their respective clinics in the prior 6 months (from the point of 
their viral load result) were defined as lost to follow-up. Meningitis free survival was defined as 
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having not suffered from clinical cryptococcal meningitis during the six month period after the 
HIV viral load testing. 
Ethic Reviews 
We obtained ethical review and approval from the Makerere University School of Medicine 
research and ethics committee, as well as Uganda National Council of Science and Technology, 
and the University of Minnesota. A waiver for informed consent was obtained as CrAg testing 
was performed on leftover plasma samples, and the study posed no more than minimal risk to 
participants. 
Statistical methods 
Data analysis was primarily descriptive with variables summarized by mean with 95% 
confidence interval (CI), median with inter -quartile range (IQR), and number (percentage). We 
tested continuous variables via nonparametric Wilcoxon Rank-Sum test and categorical data via 
Chi-square. We additionally used logistic regression to assess whether CrAg-positivity was 
associated with quantitative HIV viral load thresholds.  
Costing 
Once CrAg prevalence was determined, we used the inverse to calculate the number needed to 
test to detect one CrAg+ person. The cost of CrAg screening using the lateral flow assay in 
Uganda is $3.50 (17). We multiplied the cost of screening by the number needed to test to 
identify the cost to detect one CrAg positive person.  
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RESULTS 
Prevalence of Cryptococcal Antigenemia in ART-experienced HIV patients with virologic 
failure 
Overall 368,174 adult HIV patients had viral load testing from September 2017 to January 
2018. We found 5,348 patients had virologic failure and left over plasma samples. We found 73 
patients without left over samples for CrAg testing. Of the randomly selected 1,186 selected 
patients; 588 were from Central region, 191 from the East, 147 from the North, and 260 from the 
West. These samples were from 96 of the 127 districts in Uganda. Table 1 shows a summary of 
demographic and clinical characteristics of the study population by CrAg result. Of the 1,186 
samples tested, 61% (724/1,186) were collected from women. Participants’ had a mean (+SD) 
age of 36 (10) years and ranged 18 to 75 years. Among 1,186 ART-experienced persons with 
plasma viral loads >1000 copies/mL, we identified 35 CrAg positive persons equating to a CrAg 
prevalence of 3.0% (95%CI, 2.1% to 4.1%). Among those with virologic failure, the median 
HIV-1 viral load was 4-fold higher among CrAg-positive persons as compared with CrAg-
negative persons (46,000 vs. 12,000 copies/mL; P<0.001).  
Distribution of HIV-1 viral load among CrAg positive patients 
Among the 1,186 persons, 65% (767/1,186) had viral loads ≥5,000 copies/mL. Overall, 
91% (32/35) of CrAg-positive persons had viral loads >5,000 copies/mL compared with 64% 
(735/1,151) of CrAg-negative (Odds Ratio = 6.0; 95% CI, 1.8 to 19.8, P=0.001). CrAg 
prevalence increased among higher viral loads with 4.2% (32/768) CrAg-positivity among those 
with >5,000 copies/mL versus 0.7% (3/419) CrAg-positivity among those with <5,000 
copies/mL. Figure 1 displays prevalence of CrAg positivity with respect to HIV viral load.  
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Outcomes of CrAg positive patients with virologic failure  
Among the 35 CrAg-positive persons, we obtained 6-month survival data for 25 persons. 
We didn’t get outcome data on the other 10 CrAg positive persons because efforts to contact 
their respective clinicians or to access their medical files were futile. Of the 25 CrAg positive 
persons with outcome data, 16 (64%) were known to be alive, 7 (28%) were confirmed dead, and 
2 (8%) were lost to follow up.  
Of the 25 CrAg-positive, only 1 person had a history of treatment for cryptococcal meningitis 2 
years prior and was taking fluconazole for secondary prophylaxis. Of the 25 CrAg positive 
persons, 17 were getting their first ever CrAg test. Five survivors were known to have been CrAg 
tested and received pre-emptive therapy fluconazole around the time of their viral load result. 
Another two patients developed cryptococcal meningitis during these 6 months were treated and 
survived. Thus, meningitis-free survival at 6-months was 61% (14/23; 95%CI, 35% to 76%). 
Absent fluconazole receipt (n=19), 6-month meningitis free survival was 42% (8/19; 95%CI, 
20% to 67%).  
We also did an analysis including those who were lost to follow up. We used 6 month outcome 
findings from a CrAg+ cohort in Uganda which found 14% mortality rate, 77% meningitis free 
survival and 9% progression to meningitis(10). If we applied this to the 10 without survival data, 
we would have 8 who survived meningitis free,1 who died and 1 who developed cryptococcal 
meningitis. This would then make a 63% (22/35 )meningitis free survival rate. If we were to 
consider that all the 10 without survival data died then the meningitis free survival would be 40% 
(14/35).  
We determined the likely outcome of those lost to follow up (including those without outcome 
data) by comparing their sex, median ages and viral loads with those who survived and died. We 
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used the Fischer’s exact test for the sex comparison across the three groups and found no 
significant difference (p=0.42). The Kruskal Wallis test was used to compare the medians for age 
and viral load across the three groups and the test was not significant for both age (p = 0.42) and 
viral load (p = 0.10). Therefore, the likely outcome of the individuals lost to follow up may be 
similar to those who were accounted. 
Cost of CrAg screening 
 We identified 4.2% CrAg prevalence among persons with a HIV viral load >5000 
copies/mL. Thus, the number needed to test to detect one CrAg positive person is 25. At a cost of 
$3.50 for the CrAg lateral flow assay(17), the cost to detect one CrAg positive person among 
those with virologic failure is $87.50.  
 
Discussion 
The CrAg prevalence was 3.0% in ART-experienced HIV patients with virologic failure 
and 4.2% among those with >5,000 HIV RNA copies/mL. To our knowledge, this is the first 
study to evaluate CrAg prevalence in ART-experienced patients with virologic failure, 
irrespective of CD4 count. This CrAg prevalence rate was similar to that in ART-experienced 
populations in studies in South Africa 2.8% , Brazil 3.1% (18-19), and in Ethiopia 4.1% (20) but 
lower than that in studies in Nigeria (8.9%) and Ethiopia (8.4%) though all these studies included 
participants responding to ART or didn’t report viral loads (12, 16).  CrAg positivity was shown 
to significantly increase with higher viral loads indicating a higher risk for cryptococcosis in 
people with more fulminant virologic failure. We found an all-cause 6-month meningitis-free 
survival rate of 61% among CrAg-positive persons, of whom at least 6 survivors received 
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fluconazole therapy. Absent this fluconazole therapy, meningitis-free survival was ~40%, 
although the 95% confidence interval was wide.  
We calculated that it would cost $87.50 to detect one CrAg positive person if screening is 
performed among persons with viral loads of >5000 copies/mL. In 2018, Uganda had 951,692 
adult HIV viral load samples tested; 858,426 were suppressed, 6,661 tests were rejected, and  
86,603were virologic failures (VL >1,000)(14). From our sample, one could assume 64% of 
those with virologic failure had a viral load >5000 copies/mL. Thus 55,426 persons would be 
screened per year, and 2,327 would be CrAg positive. Thus, of the 951,692 total viral load 
samples received, the additional cost would be ~$193,991 in total, or $0.20 per viral load sample 
received.  
As HIV programs ramp up test and treat and scale up virologic monitoring, we have 
observed increasing proportions of persons with cryptococcal meningitis presenting as ART-
experienced persons with undetected virologic failure (11, 21). WHO guidelines recommend 
CrAg screening for persons with CD4<100 cells/L prior to initiating ART (9, 22), however, for 
the ART experienced persons no guidelines exist. Given that virologic monitoring is emphasized 
more than CD4 monitoring in this population, using a viral load threshold to identify who needs 
CrAg screening becomes more pertinent. The guidelines acknowledge that CrAg screening in 
ART-experienced persons needs to be further evaluated. Based on our findings, in the absence of 
CD4 monitoring, we would recommend CrAg screening among persons with virologic failure 
>5,000 copies/mL as this threshold where we found a CrAg prevalence of 4.2%.  
The study had limited access to patient medical information, thus missed some clinically 
relevant data, such as CD4 cell count, which could have been useful in further characterizing the 
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population of interest. This could also have introduced information bias in characterizing patients 
as meningitis free. The potential seasonal distribution of cryptococcal infections may have 
influenced prevalence results. While we only tested plasma specimens, whether dried blood spots 
would have a different CrAg prevalence is unclear as the CrAg LFA sensitivity is lower in dried 
blood spots than in plasma due to the extraction process (unpublished data). Viral load testing is 
being scaled up replacing CD4 monitoring yet absolute CD4 counts provide the risk stratification 
to target evaluation for opportunistic infections, including CrAg screening.  The cost of CD4 
testing (~$6) is more than the cost of CrAg testing (<$4), thus from a program implementation 
perspective, using CD4 testing to then narrow the pool to select for CrAg testing is not efficient, 
unless a CD4 is already being performed (17, 23).  We should consider expanding the threshold 
for CrAg testing by including those with viral load >5,000 copies/mL which would decrease the 
amount of CrAg testing by 35% (419/1186) yet still detect >90% (32/35) of CrAg+ persons. The 
limitations of this approach are that it would be dependent on the turn-around time for viral load. 
Another limitation of the study was that we did not perform CrAg titers. This information could 
be useful to determine if persons with low plasma CrAg LFA titers <1:20 (24), may respond well 
to prompt switching to second-line ART only. The strengths of the study include generalizability 
of the results because we had access to samples from all regions of the country. This study also 
provided an opportunity to pilot implementation of the Uganda CrAg screening guidelines, 
which now include CrAg screening individuals with virologic failure and those with a positive 
symptom screen in the advanced HIV disease pathway(13). Further studies in different 
geographical areas where cryptococcosis is common are warranted in order to characterise the 
epidemiology of cryptococcal disease among persons failing ART and to evaluate the cost 
effectiveness of using viral load testing as an entry point to CrAg screening in this population. 
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Prospective studies on the implementation of such a screening strategy and clinical outcomes 
with fluconazole preemptive therapy are needed to further characterize this potential strategy to 
reduce AIDS-related deaths among persons with virologic failure. 
This study shows that ART-experienced people failing HIV therapy are at risk for 
disseminated cryptococcal antigenemia and eventually cryptococcal meningitis or death and 
demonstrates the feasibility of linking CrAg screening to viral load monitoring.  In order to 
further avert cryptococcosis among individuals with virologic failure, WHO should recommend 
CrAg screening in persons with virologic failure with viral loads ≥ 5000/mL. Cost effective 
studies are needed to establish whether CrAg screening based on viral load thresholds (alongside 
CD4 counts) would be feasible. Studies to determine the association of virologic failure 
independent of CD4 and CrAg are needed. Prospective studies among ART-experienced 
populations to further evaluate the optimal viral load threshold for CrAg testing, timing of ART 
switch, implementation of this strategy, and the potential benefit of CrAg screening are 
warranted. 
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 Table 1; clinical characteristic of participants by plasma CrAg status 
Characteristic 
CrAg Positive 
(N = 35) 
CrAg Negative 
(N=1151) 
P-value 
Age, years 
35 
(28 to 45) 
36 
(30 to 43) 
0.92 
Women 20 (57%) 704 (62%) 0.55 
HIV-1 Viral Load, 
copies/mL 
46,400 
(17,300 to 56,000) 
12,000 
(3,020 to 69,800) 
<0.001 
HIV-1 Viral Load 
>5000 copies/mL 
32 (91%) 735 (64%) 0.001 
Duration of HIV Therapy 
0.5-1 year 4 (12%) 69 (6.7%) 0.22 
1-2 years 4 (12%) 144 (14%) 0.77 
2-5 years 12 (36%) 400 (39%) 0.80 
>5 years 13 (39%) 424 (41%) 0.86 
 
Values are median (IQR) or n (%). P-Value from Wilcoxon rank-sum test for medians and Chi 
Square test for proportions. Abbreviations: CrAg = Cryptococcal Antigen 
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Figure 1; Cryptococcal Antigen (CrAg) prevalence by HIV-1 plasma viral load among 
Ugandans undergoing routine virologic monitoring on HIV therapy 
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